Loading clinical trials...
Loading clinical trials...
Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma
Conditions
Interventions
Lorlatinib
Cyclophosphamide
+2 more
Locations
13
United States
Children's Hospital Los Angeles
Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Children Hospital of Colorado
Aurora, Colorado, United States
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
University of Chicago, Comer Children's Hospital
Chicago, Illinois, United States
Childrens Hospital Boston, Dana-Farber Cancer Institute.
Boston, Massachusetts, United States
Start Date
September 5, 2017
Primary Completion Date
August 22, 2024
Completion Date
January 31, 2025
Last Updated
September 15, 2025
NCT03050268
NCT04308330
NCT06721689
NCT06395103
NCT06541262
NCT06057948
Lead Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions